Biograil

Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device avoids mechanical moving components and makes use of the body’s own peristaltic forces to facilitate the delivery of the biologic efficiently into the gastrointestinal wall. The team behind Biograil is a combination of seasoned entrepreneurs with long experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet to be approved by the FDA.

Press releases

Press
17. February 2022

Biograil Secures Seed 2 Funding for Oral Delivery Device for Biologics

COPENHAGEN, DENMARK, Jan 17th, 2022 – Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of biologics that would otherwise be injected, announced the closing of a Seed 2 funding of 3.2 million Euro. The Round was led by Danish Megatrend Invest a/s with strong support from other prior investors including Verve Ventures, a Swiss Investment group and Sanner Ventures, a German family office. Evonik Venture Capital participated as a new investor. Ev
 
Press
15. January 2020
Biograil secures seed funding for oral delivery device with potential to transform market for injectables
Biograil ApS, an innovative biotechnology company developing a unique oral device for delivery of biologics that would otherwise be injected, today announced the closing of a seed funding of 3 Million Euro (with potential to expand to 5 Million Euro). The investor Syndicate was led by the experienced German seed investor High-Tech Gründerfonds (HTGF) and included Danish Megatrend Invest a/s, Swiss Investment group as well as a Danish private healthcare investor. The device is being developed a
 

Info & Contact

Karsten Lindhardt (CEO)
Phone:
+45 21 66 39 41
Web:
biograil.com

Address

Biograil ApS
Baldersbuen 2
2640 Hedehusene
Denmark

In portfolio

20. Dec 2019

Sector

HTGF Manager

 
Dr. Anke Caßing, Principal / Authorized Signatory